NCT00002199View on ClinicalTrials.gov

A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.

PHASE3CompletedINTERVENTIONAL

Enrollment

550

Participants

Timeline

Start Date

Not specified

Conditions

HIV Infections

Interventions

DRUG

Indinavir sulfate

DRUG

Lamivudine/Zidovudine

DRUG

Abacavir sulfate

Trial Locations (1)

02215

Beth Israel Deaconess Med Ctr, Boston

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Glaxo Wellcome

INDUSTRY

NCT00002199 - A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects. | Biotech Hunter | Biotech Hunter